Citadel Advisors’s Frazier Lifesciences Acquisition Corporation Warrant FLACW Stock Holding History

Citadel Advisors’s Portfolio FLACW Stock Details FLACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,495	Closed	-$1K	–	14112
2022 Q2	$1K	Sell	10,495 -156,612	-94%	-$27.2K	﹤0.01%	12744
2022 Q1	$38K	Sell	167,107 -9,192	-5%	-$3.99K	﹤0.01%	12981
2021 Q4	$102K	Sell	176,299 -4,633	-3%	-$3.24K	﹤0.01%	12710
2021 Q3	$114K	Sell	180,932 -2,400	-1%	-$2.15K	﹤0.01%	12711
2021 Q2	$204K	Hold	183,332	–	–	﹤0.01%	12122
2021 Q1	$165K	Buy	+183,332	New	+$310K	﹤0.01%	11940

Other funds holding FLACW

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return

MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Citadel Advisors's FLACW Position: Q3 2022 in Review

Citadel Advisors sold out of Frazier Lifesciences Acquisition Corporation Warrant (FLACW) in Q3 2022, closing a stake of 10,495 shares — an estimated $1K sold.

Citadel Advisors first reported a position in FLACW in Q1 2021 and held it in 6 quarters. The position peaked at $204K in Q2 2021. 21 funds tracked by Wall St. Rank hold FLACW as of Q3 2022.

Citadel Advisors reported no remaining Frazier Lifesciences Acquisition Corporation Warrant position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 10,495 Frazier Lifesciences Acquisition Corporation Warrant shares in Q3 2022, an estimated $1K.
Citadel Advisors first reported a position in Frazier Lifesciences Acquisition Corporation Warrant in Q1 2021 and held it in 6 quarters.
Citadel Advisors's Frazier Lifesciences Acquisition Corporation Warrant position peaked at $204K in Q2 2021.
21 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Warrant as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.